More than 90% of SM patients harbor a somatic gain-of-function mutation in the KIT gene, namely KITD816V, that leads to a constitutional activity of the KIT receptor in a ligand-independent fashion [3]. This evidence concerns the gene KIT and systemic mastocytosis.